Edition:
India

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

14.90USD
10:57pm IST
Change (% chg)

$0.05 (+0.34%)
Prev Close
$14.85
Open
$14.90
Day's High
$15.00
Day's Low
$14.85
Volume
17,247
Avg. Vol
59,358
52-wk High
$18.55
52-wk Low
$10.77

Latest Key Developments (Source: Significant Developments)

Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Meridian Bioscience Inc : :Meridian Bioscience Inc - ‍announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary​.Meridian Bioscience - ‍since issuance of FDA warning letter, ‍Magellan​ initiated comprehensive quality system remediation activities​.  Full Article

U.S. FDA issues warning letter to Magellan Diagnostics
Monday, 23 Oct 2017 

Oct 23 (Reuters) - ‍U.S. Food and Drug Administration : :‍U.S. Food and Drug Administration says issued a warning letter to Magellan Diagnostics Inc​.‍U.S. FDA - Magellan diagnostics has until Nov. 10, to notify FDA about specific steps co has taken to address violations, to prevent them from recurring​.U.S. FDA says in letter that Magellan marketed significantly modified versions of two of its blood lead testing systems without FDA's required approval​.‍U.S. FDA - Inspection showed Magellan altered two of its blood lead testing systems after they were already FDA cleared.‍U.S. FDA - During inspection investigators observed violations, including failing to submit medical device reports regarding discrepancies in test results​.  Full Article

Meridian bioscience comments on preliminary fiscal 2017 operating results
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Meridian Bioscience Inc :Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance.Sees FY 2018 GAAP earnings per share $0.59 to $0.62.Sees FY 2017 GAAP earnings per share $0.50 to $0.51.Sees FY 2018 revenue up 3 to 6 percent.Sees FY 2018 revenue $207 million to $212 million.Sees FY 2017 revenue about $200.5 million.Sees FY 2018 non-GAAP earnings per share $0.65 to $0.68.FY2018 earnings per share view $0.68, revenue view $202.4 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $0.67, revenue view $198.4 million -- Thomson Reuters I/B/E/S.Meridian Bioscience Inc - expect ‍C.difficile Toxins A/B & GDH test to launch in late fiscal 2018​.Meridian - ‍expect to complete development on H.pylori/Clarithromycin resistance assay during fiscal 2018, enter clinical trials in early 2019​.Meridian Bioscience Inc - ‍expect to launch illumigene CMV late in fiscal 2018​.  Full Article

MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER.SAYS JACK KENNY APPOINTED CEO.‍KENNY HAS ALSO BEEN APPOINTED TO MERIDIAN'S BOARD OF DIRECTORS EFFECTIVE OCTOBER 9, 2017​.A. KRAEUTLER STEPS DOWN AS CEO AND TAKES TITLE OF EXECUTIVE CHAIRMAN​.‍JOHN (JACK) A. KRAEUTLER STEPS DOWN AS CEO​.  Full Article

Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line
Wednesday, 9 Aug 2017 

Aug 8 (Reuters) - Meridian Bioscience Inc : :Meridian Bioscience Inc- ‍Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B​.  Full Article

Meridian Bioscience reports Q3 EPS of $0.21
Thursday, 28 Jul 2016 

Meridian Bioscience Inc : Meridian Bioscience reports third quarter 2016 operating results, declares regular cash dividend, and updates fiscal 2016 guidance . FY 2016 earnings per share view $0.88, revenue view $203.4 million -- Thomson Reuters I/B/E/S . Sees FY 2016 NON-GAAP earnings per share $0.86 to $0.90 . Q3 earnings per share $0.21 . Sees FY 2016 revenue $195 million to $200 million . Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S .Q3 revenue $50.7 million versus I/B/E/S view $52.8 million.  Full Article

Meridian Bioscience Inc acquires Magellan Diagnostics Inc
Friday, 25 Mar 2016 

Meridian Bioscience Inc:Has completed the acquisition of Magellan Biosciences Inc and its wholly owned subsidiary Magellan Diagnostics Inc.Expects Magellan to be accretive to earnings per share during the second half of calendar 2017.Says Meridian will finance purchase price of $66 million using a combination of cash on hand and a $60 million five-year term loan.  Full Article

Meridian Bioscience Inc reaffirms FY 2016 guidance
Wednesday, 27 Jan 2016 

Meridian Bioscience Inc:Reaffirms FY 2016 2016 guidance of per share diluted earnings between $0.86 and $0.90 on net revenues of $195 million to $200 million.  Full Article

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments